Built on insights from the Lyfegen Agreements Library - home to 8,00 public reimbursement contracts - the Q2 2025 Drug Contracting Trends Report focuses on how pharma and payers are solving today’s biggest access challenges, including obesity and GLP-1-driven demand.
From the complexity of high-cost gene therapies to the global surge in GLP-1 and obesity demand, see how cost pressures, clinical uncertainty, and policy shifts are driving innovative drug contracting strategies.
Innovative Models for Managing High-Cost Therapies
Discover how payers are using budget caps, outcome guarantees, dose-based pricing, and conditional reimbursement to contain costs and manage uncertainty around high-cost therapies, from gene therapies to obesity drugs.
Latest Agreements and Trends
Gain real-world insights from 820 newly identified agreements across 25 countries, and explore the growing impact of outcome guarantees, budget caps, installment payments, and restricted access models. Plus, take a deep dive into the access challenges and contracting strategies shaping the future of GLP-1s and obesity care.
Regional Perspectives
Track developments across Europe, North America, and Asia, highlighting how local regulations and strategies continue to evolve in 2025.
Strategic Takeaways for Pharma
Understand how manufacturers can navigate today’s high-stakes access environment by:
✔️ Supporting policy and advocacy efforts that reframe obesity as a chronic disease
✔️ Leveraging real-world evidence to enhance impact-based pricing
✔️ Crafting segmented value stories for high-risk patient groups
✔️ Building economic models for population-level and volume-based deals
✔️ Investing in long-term outcomes data to support future negotiations
* By sending this message, you agree to our privacy policy.
Sign up & be the first to know about INNOVATIONS
* By sending this message, you agree to our privacy policy.
